Business Wire

Brain Corp Continues European Growth, Demonstrates ‘Inventory Scan’ Technology with Tennant Company, a First-of-its-kind Robotic Solution for Automated Analytics in Retail

28.4.2022 11:00:00 EEST | Business Wire | Press release

Share

Brain Corp, an artificial intelligence (AI) company creating transformative core technology in robotics, and Tennant Company, today announced the European demonstration of Inventory Scan, a powerful new data capture accessory that will be fitted to Tennant’s autonomous floor scrubbers to autonomously scan and report key detail on in-store inventory.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428005188/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Brain Corp Demonstrates ‘Inventory Scan’ Technology with Tennant Company at Interclean (Photo: Business Wire)

"By adding Inventory Scan to new or existing robotic scrubber fleets, retailers are immediately able to access critical in-store inventory data in near real-time," said Dave Ross, Vice President of Business Development at Brain Corp. "Knowing where an item is, if it’s in stock, if it’s in the correct location, if the price is accurate, and more allows managers to operate stores with a new level of efficiency while providing optimal shopping experiences for their customers. Based on the success we’ve seen in the US with the technology, we are excited to get feedback from those in the European market.”

Utilizing a first-of-its-kind, multi-purpose design, the powerful new scanning accessory will be fitted to Tennant’s floor scrubbers powered by Brain Corp’s BrainOS autonomy software platform. The new, cloud-connected Inventory Scan tower is able to capture data as it moves autonomously around the store. Reports are then delivered to the store managers, providing numerous insights including: verification of pricing accuracy, planogram compliance, product stock levels and product localization. Each function negates the need for time-consuming and potentially inaccurate manual processes, which often lead to lost revenue opportunities, waste caused by overordering and not enough attention given to shoppers.

“The new integrated inventory analytics accessory is filling a much-needed AI and data process gap for retailers,” said Maggie Koester, Global Product Manager at Tennant Company. “What makes this solution compelling is the ability to integrate with retailers’ inventory management systems utilizing their existing floor scrubbers. By adding data collection functionality to these machines, we are dramatically improving how stores operate. Inventory Scan allows retailers to be more efficient and effective by reducing the disruption of labor-intensive manual approaches. Our vision is that data collection and floor care become fully automated so our customers can focus on managing their businesses.”

Interclean 2022 to Host the Unveiling of the Technology in Amsterdam

Inventory Scan will have its European introduction on May 10-13, 2022 at the RAI Centre in Amsterdam, on Brain Corp stand - Hall 7, Booth 108.

"This new product marks the beginning of realizing the next phase in our company's vision and continued growth in Europe as well as the US," said Dr. Eugene Izhikevich, CEO of Brain Corp. "We are actively taking BrainOS-powered robots from primarily task-oriented machines to in-store data acquisition platforms. This delivers critical insights and this will add significant ROI for European retailers as we continue to expand our activity in Europe and beyond."

Brain Corp Sees 100% Year-on-year Growth in European Countries Deploying BrainOS-powered Robots

Partnering with many of the world’s leading OEMs (Original Equipment Manufacturers) including Minuteman, Karcher, Nilfisk and Tennant, autonomous robotic scrubbers, powered by Brain Corp’s AI operating system BrainOS®, are now operational across multiple sectors in 16 European countries.

New countries seeing robotic deployments include Belgium, Denmark, Finland, Luxembourg, Norway and Switzerland. Countries implementing the largest numbers of autonomous robots include France, Spain, Portugal, Italy, Germany, the UK, and the Netherlands.

“There’s no doubt that we’re starting to see the tipping point where the integration of robotics with human teams has gone beyond a novelty and become a practical solution for maintaining sustainable operations,” said Michel Spruijt, SVP International Business at Brain Corp. “We’re seeing significant increases in demand across multiple industry sectors which have been impacted most severely by labor shortages and increased operational strain as a result of the pandemic. Autonomous robotics have proven themselves to be a very effective and welcome solution to these growing problems.”

In 2021, the BrainOS®-powered fleet of autonomous mobile robots hit a major milestone of 500 million square feet covered (46.45 million square meters) autonomously in Europe. In total, over 46,000 hours were given back to workers during the year with the most significant growth coming within retail, logistics, and warehousing sectors.

About Brain Corp

Brain Corp is the global leader in robotic AI software that powers the largest fleet of autonomous mobile robots (AMRs) operating in commercial public spaces. Global OEM partners use the company’s cloud-connected platform, BrainOS®, to create scalable, self-driving robots that are used by end customers to clean floors, move inventory, and sense environmental data - turning manual operations into automated workflows. Fortune 500 brands across multiple verticals benefit from the growing portfolio of BrainOS®-powered robots and our industry-leading privacy, safety and efficiency tools that make managing and scaling automation easier. Brain Corp currently powers more than 20,000 AMRs, representing the largest fleet of its kind in the world.

For more information, visit www.braincorp.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Josh Stanbury | josh@sjspr.co | 416-628-7441

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye